Although our study employed patient-derived glioblastoma stem cells and relied on functional assays to assess treatment impact, future studies incorporating flow cytometry-based analysis of stemness markers (e.g., Olig2, Sox2, Nestin) will be important to further characterize phenotypic shifts induced by FGFR inhibition and radiation. This evidence concerns the gene NES and glioblastoma.